Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 6
2002 6
2003 10
2004 19
2005 5
2006 9
2007 15
2008 19
2009 28
2010 34
2011 36
2012 40
2013 40
2014 65
2015 53
2016 35
2017 36
2018 30
2019 19
2020 21
2021 28
2022 20
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

500 results
Results by year
Filters applied: . Clear all
Page 1
[Olmesartan-associated Enteropathy].
Zou L, Wang Q, Li Y, Yang AM. Zou L, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021 Dec 30;43(6):986-990. doi: 10.3881/j.issn.1000-503X.13268. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021. PMID: 34980342 Review. Chinese.
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent years have described a severe gastrointestinal adverse event with chronic diarrhea,intestinal malabsorption,and weight loss after th …
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent …
Drugs for hypertension.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 May 18;62(1598):73-80. Med Lett Drugs Ther. 2020. PMID: 32555118 No abstract available.
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. ...The safety and tolerability profiles of sacubitril/valsarta

…
Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitr …
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Oparil S, et al. J Clin Hypertens (Greenwich). 2001 Sep-Oct;3(5):283-91, 318. doi: 10.1111/j.1524-6175.2001.01136.x. J Clin Hypertens (Greenwich). 2001. PMID: 11588406 Free PMC article. Clinical Trial.
The reduction in mean 24-hour SBP with olmesartan (12.5 mm Hg) was significantly greater than the reductions with losartan and valsartan (9.0 and 8.1 mm Hg, respectively) and equivalent to the reduction with irbesartan (11.3 mm Hg). All drugs were well tolerated. The autho …
The reduction in mean 24-hour SBP with olmesartan (12.5 mm Hg) was significantly greater than the reductions with losartan and valsar …
Olmesartan.
Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Al-Jallal AAM. Al-Majed AA, et al. Profiles Drug Subst Excip Relat Methodol. 2017;42:241-286. doi: 10.1016/bs.podrm.2017.02.005. Epub 2017 Mar 31. Profiles Drug Subst Excip Relat Methodol. 2017. PMID: 28431778
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. ...Comprehensive pharmacology is also presented (pharmacologi …
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood …
Olmesartan-induced enteropathy.
Onteddu NK, Pulivarthi VSKK, Ginnavaram M, Kedika R. Onteddu NK, et al. BMJ Case Rep. 2018 Oct 2;2018:bcr2018224411. doi: 10.1136/bcr-2018-224411. BMJ Case Rep. 2018. PMID: 30279248 Free PMC article.
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. ...Cessation of the offending drug resulted in improvement of clinical symptoms and also hospital admi …
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weigh …
Triple-combination therapy in the treatment of hypertension: a review of the evidence.
Düsing R, Waeber B, Destro M, Santos Maia C, Brunel P. Düsing R, et al. J Hum Hypertens. 2017 Aug;31(8):501-510. doi: 10.1038/jhh.2017.5. Epub 2017 Feb 23. J Hum Hypertens. 2017. PMID: 28230062 Review.
Randomised controlled trials (RCTs) have shown that triple combinations of amlodipine/valsartan/hydrochlorothiazide, amlodipine/olmesartan/hydrochlorothiazide and amlodipine/telmisartan/hydrochlorothiazide produce greater BP reductions, with greater proportions of patients …
Randomised controlled trials (RCTs) have shown that triple combinations of amlodipine/valsartan/hydrochlorothiazide, amlodipine/olmesarta …
Olmesartan-associated sprue-like enteropathy.
Aoyama N, Inokuma T, Nakanishi Y, Fukuda A. Aoyama N, et al. BMJ Case Rep. 2022 Dec 23;15(12):e254189. doi: 10.1136/bcr-2022-254189. BMJ Case Rep. 2022. PMID: 36564092 No abstract available.
Antihypertensive effect of sacubitril/valsartan: a meta-analysis.
De Vecchis R, Ariano C, Soreca S. De Vecchis R, et al. Minerva Cardioangiol. 2019 Jun;67(3):214-222. doi: 10.23736/S0026-4725.19.04869-2. Epub 2019 Mar 18. Minerva Cardioangiol. 2019. PMID: 30895762 Review.
The mean reductions in systolic blood pressure (msSBP) and diastolic blood pressure (msDBP) in the sitting position as well as the mean reductions in ambulatory systolic blood pressure (maSBP) and ambulatory diastolic blood pressure (maDBP), were assumed as efficacy endpoints. …
The mean reductions in systolic blood pressure (msSBP) and diastolic blood pressure (msDBP) in the sitting position as well as the mean redu …
Olmesartan-Induced Enteropathy.
Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E. Adike A, et al. Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):230-232. doi: 10.14797/mdcj-12-4-230. Methodist Debakey Cardiovasc J. 2016. PMID: 28289500 Free PMC article.
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea …
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are …
500 results